The Power of Breathing

Technology & Product Pipeline

The cardiovascular and neurological effects of breathing excercises have been known for centuries. In fact, unaided slow breathing is a key element of relaxation techniques such as meditation and yoga but is generally considered unproven and impractical for treating chronic diseases such as hypertension and/or heart failure.

InterCure’s broadly patented Device-Guided Breathing technology ingeniously takes advantage of the human body’s natural tendency to follow external rhythms and has broadly patented an interactive “feed-forward” concept. The technology composes rhythmic guiding tones, in real time, while measuring the user’s individual respiration pattern. By dynamically manipulating and recalculating these personalized tones it guides users into a Therapeutic Zone, subliminally, with almost no conscious effort on the user’s part leading to unprecedented efficacy, ease-of-use and compliance.

Nine well-designed clinical trials prove that RESPeRATE delivers all-day blood pressure reductions beyond concurrent treatments such as medication, diet, and exercises. The significant results enabled InterCure to win the first ever FDA-clearance for a hypertension treatment device (510K with clinical trials), an OTC clearance, as well as a CE mark, Korean FDA clearance and approvals in most other key markets.

InterCure has designated sleeplessness and heart failure as its next two target disease states. InterCure’s heart failure product, named inTone, successfully met or exceeded primary endpoints in three phase 2a clinical studies and the results elicited great excitement in the heart failure community. The company plans to continue the development of these products and to introduce them within 18-24 months.

Next: Press Releases